Overview

Long-Term Evaluation of BIIB067

Status:
Active, not recruiting

Trial end date:
2024-06-13

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to evaluate the long-term safety and tolerability of BIIB067 in participants with amyotrophic lateral sclerosis (ALS) and confirmed superoxide dismutase 1 (SOD1) mutation. The secondary objectives are to evaluate the pharmacokinetic (PK), pharmacodynamic (PD), biomarker effects, and efficacy of BIIB067 administered to participants with ALS and a confirmed SOD1 mutation.

Phase:

Phase 3

Details

Lead Sponsor:

Biogen

Collaborator:

Ionis Pharmaceuticals, Inc.

Treatments:

Superoxide Dismutase